|
Filed by the Registrant ☒
|
| |
Filed by a Party other than the Registrant
☐
|
|
☐
|
| |
Preliminary Proxy Statement
|
|
☐
|
| |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☒
|
| |
Definitive Proxy Statement
|
|
☐
|
| |
Definitive Additional Materials
|
|
☐
|
| |
Soliciting Material under §240.14a-12
|
|
☒
|
| |
No fee required
|
|
☐
|
| |
Fee paid previously with preliminary materials
|
|
☐
|
| |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
|
Sincerely,
|
| |
|
|
|
| |
|
|
/s/ Paul Badawi
|
| |
|
|
Paul Badawi
|
| |
|
|
President and Chief Executive Officer
|
| |
|
|
•
|
To elect David Badawi, M.D., Tamara Fountain, M.D. and Donald Zurbay as Class III Directors to serve until the 2027 Annual Meeting of Stockholders and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal;
|
|
•
|
To ratify the appointment of Deloitte Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and
|
|
•
|
To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
|
By Order of the Board of Directors
|
| |
|
|
|
| |
|
|
/s/ Paul Badawi
|
| |
|
|
Paul Badawi
|
| |
|
|
President and Chief Executive Officer
|
| |
|
|
•
|
To elect David Badawi, M.D., Tamara Fountain, M.D., and Donald Zurbay as Class III Directors to serve until the 2027 Annual Meeting of Stockholders and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal;
|
|
•
|
To ratify the appointment of Deloitte Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and
|
|
•
|
To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
|
•
|
“FOR” the election of David Badawi, M.D., Tamara Fountain, M.D., and Donald Zurbay as Class III Directors to serve until the 2027 Annual Meeting of Stockholders and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal; and
|
|
•
|
“FOR” the ratification of the appointment of Deloitte Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
|
|
•
|
by Internet—You can vote over the Internet at www.proxyvote.com by following the instructions on the Internet Notice or proxy card;
|
|
•
|
by Telephone—You can vote by telephone by calling 1-800-690-6903 and following the instructions on the Internet Notice or proxy card;
|
|
•
|
by Mail—If you received printed copies of the proxy materials, you can vote by mail by signing, dating and mailing the proxy card; or
|
|
•
|
Electronically at the Meeting—If you attend the Annual Meeting online, you will need the 16-digit control number included on your Internet Notice, on your proxy card, or on the instructions that accompanied your proxy materials to vote electronically during the meeting.
|
|
•
|
by submitting a duly executed proxy bearing a later date;
|
|
•
|
by granting a subsequent proxy through the Internet or telephone;
|
|
•
|
by giving a written notice of revocation to the Secretary of Sight Sciences prior to or at the Annual Meeting; or
|
|
•
|
by voting online at the Annual Meeting.
|
|
•
|
irrelevant to the business of the Company or to the business of the Annual Meeting;
|
|
•
|
related to material non-public information of the Company, including the status or results of our business since our last periodic report filing;
|
|
•
|
related to any pending, threatened or ongoing litigation;
|
|
•
|
related to personal grievances;
|
|
•
|
derogatory references to individuals or that are otherwise in bad taste;
|
|
•
|
substantially repetitious of questions already made by another stockholder;
|
|
•
|
in excess of the two-question limit;
|
|
•
|
in furtherance of the stockholder’s personal or business interests; or
|
|
•
|
out of order or not otherwise suitable for the conduct of the Annual Meeting as determined by the Chairperson or Secretary in their reasonable judgment.
|